



Urban Novak

Contact

Urban Novak

Publications (19)

Passweg J, Baldomero H, Ansari M, Arber C, Chalandon Y, Daskalakis M, Diepold M, Diesch-Furlanetto T, Duchosal M, Gerull S, Güngör T, Heim D, Hitz F, Holbro A, Masouridi-Levrat S, Nair G, Novak U, Pabst T, Renner C, Stussi G, Schneidawind D, Schanz U, Wannesson L, Halter J, Swiss Blood Stem Cell Transplantation Group (SBST). Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997–2021. *Hematol Oncol* 2023

Novak U, Fehr M, Schär S, Dreyling M, Schmidt C, Derenzini E, Zander T, Hess G, Mey U, Ferrero S, Mach N, Boccomini C, Böttcher S, Voegeli M, Cairoli A, Ivanova V, Menter T, Dirnhofer S, Scheibe B, Gadiant S, Eckhardt K, Zucca E, Driessen C, Renner C. Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13). *EClinicalMedicine* 2023; 64:102221.

Zander T, Pabst T, Schär S, Aebi S, Mey U, Novak U, Lerch E, Rhyner Agocs G, Goede J, Maniecka Z, Hayoz S, Rüfer A, Renner C, Driessen C. Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial. *Leukemia* 2023; 37:699–701.

Hitz F, Lang N, Mey U, Mingrone W, Moccia A, Taverna C, Novak U, Stenner F, Schmidt A, Mamot C, Fischer N, Putora P. Decision-making among experts in advanced Hodgkin Lymphoma. *Oncology* 2022

Stathis A, Mey U, Schär S, Hitz F, Pott C, Mach N, Krasniqi F, Novak U, Schmidt C, Hohloch K, Kienle D, Hess D, Moccia A, Unterhalt M, Eckhardt K, Hayoz S, Forestieri G, Rossi D, Dirnhofer S, Ceriani L, Sartori G, Bertoni F, Buske C, Zucca E, Hiddemann W. SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma. *Blood Adv* 2022; 6:3911–3920.

Schmitt A, Walter M, Herbrand A, Jörger M, Moffa G, Novak U, Hemkens L, Kasenda B. Characteristics and survival of patients with cancer with intended off-label use—a cohort study. *BMJ Open* 2022; 12:e060453.

Bonfiglio F, Bruscazzin A, Guidetti F, Terzi di Bergamo L, Faderl M, Spina V, Condoluci A, Bonomini L, Forestieri G, Koch R, Piffaretti D, Pini K, Piroso M, Cittone M, Arribas A, Lucioni M, Ghilardi G, Wu W, Arcaini L, Baptista M, Bastidas G, Beà S, Boldorini R, Broccoli A, Buehler M, Canzonieri V, Cascione L, Ceriani L, Cogliatti S, Corradini P, Derenzini E, Devizzi L, Dietrich S, Elia A, Facchetti F, Gaidano G, Garcia J, Gerber B, Ghia P, Gomes da Silva M, Gritti G, Guidetti A, Hitz F, Inghirami G, Ladetto M, López-Guillermo A, Lucchini E, Maiorana A, Marasca R, Matutes E, Meignin V, Merli M, Moccia A, Mollejo M, Montalban C, Novak U, Oscier D, Passamonti F, Piazza F, Pizzolitto S, Rambaldi A, Sabattini E, Salles G, Santambrogio E, Scarfo L, Stathis A, Stussi G, Geyer J, Tapia G, Tarella C, Thieblemont C, Tousseyn T, Tucci A, Vanini G, Visco C, Vitolo U, Walewska R, Zaja F, Zenz T, Zinzani P, Khiabanian H, Calcinotto A, Bertoni F, Bhagat G, Campo E, de Leval L, Dirnhofer S, Pileri S, Piris M, Traverse-Glehen A, Tzankov A, Paulli M, Ponzoni M, Mazzucchelli L, Cavalli F, Zucca E, Rossi D. Genetic and phenotypic attributes of splenic marginal zone lymphoma. *Blood* 2022; 139:732–747.

Piroso M, Zhang L, Hitz F, Novak U, Hess D, Terrot T, Pascale M, Mazzucchelli L, Bertoni F, Cavalli F, Zucca E, Stathis A. A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas. *Leuk Lymphoma* 2021; 63:117–123.

Herbrand A, Hemkens L, Novak U, Moffa G, Jörger M, Hoogkamer A, Diem S, Goldkuhle M, Ewald H, Briel M, Schmitt A, Kasenda B. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs. *JAMA Netw Open* 2021; 4:e210380.

Benz R, O'Meara Stern A, Cantoni N, Bargetzi M, Bianchi-Papina E, Rossi D, Passweg J, Lohri A, Berardi S, Feller A, Rauch D, Blum S, Mey U, Arn K, Andres M, Pabst T, Baumann M, Novak U, Hitz F, Hess U, Zenhausern R, Chalandon Y, Stussi G. Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. *Blood Adv* 2020; 4:3699–3707.

Herbrand A, Hemkens L, Sricharoenchai S, Novak U, Mc Cord K, Jörger M, Hoogkamer A, Ewald H, Diem S, Briel M, Schmitt A, Kasenda B. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project. *ESMO Open* 2019; 4:e000596.

Zucca E, Zander T, Bersvendsen H, Bargetzi M, Mingrone W, Krasniqi F, Dirnhofer S, Hayoz S, Hawle H, Vilei S, Ghielmini M, Kimby E, Novak U, Lohri A, Ferreri A, Rondeau S, Vanazzi A, Østenstad B, Mey U, Rauch D, Wahlin B, Hitz F, Hernberg M, Johansson A, de Nully Brown P, Hagberg H, Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. *Blood* 2019; 134:353-362.

Driessen C, Pabst T, Hitz F, Hawle H, Rondeau S, Berset C, Besse A, Besse L, Ribi K, Samaras P, Mey U, Rüfer A, Mach N, Betticher D, Cantoni N, Novak U, Müller R, Zander T. Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma. *Blood* 2018

Conconi A, Bernasconi E, Bertoni F, Gaidano G, Cavalli F, Nassi L, Kwee I, Dirnhofer S, Scherrer A, Schmid P, Novak U, Staehelin C, Battagay M, Hasse B, Darling K, Margiotta-Casaluci G, Zucca E, Swiss HIV Cohort Study (SHCS). Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals. *Hematol Oncol* 2018

Cihoric N, Tsikkinis A, Vlaskou Badra E, Glatzer M, Novak U, Aebersold D, Lössl K. Highly conformal combined radiotherapy with cisplatin and gemcitabine for treatment of loco-regionally advanced cervical cancer - a retrospective study. *Radiation Oncology* 2017

Cihoric N, Aebersold D, Yojena C, Soldatovic I, Shelan M, Scherz A, Novak U, Glatzer M, Vlaskou Badra E, Tsikkinis A, Lössl K. Highly conformal combined radiotherapy with cisplatin and gemcitabine for treatment of loco-regionally advanced cervical cancer - a retrospective study. *Radiat Oncol* 2017; 12:202.

Pestalozzi B, Novak U, Nussbaum C, Seifert B, Bigler M, Bize V, Vilei S, Rageth C, Aebi S, Borner M, Buser K, Tausch C, Dedes K, Rochlitz C, Zimmermann S, von Moos R, Winterhalder R, Ruhstaller T, Mueller A. Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10). *BMC cancer* 2017; 17:265.

Burkhard R, Bhagat G, Cogliatti S, Rossi D, Gaidano G, Pasqualucci L, Novak U. BCL2 mutation spectrum in B-cell non-Hodgkin lymphomas and patterns associated with evolution of follicular lymphoma. *Hematol Oncol* 2014

Cogliatti S, Novak U, Henz S, Schmid U, Möller P, Barth T, Swiss Group for Clinical Cancer Research (SAKK). Diagnosis of Burkitt lymphoma in due time: a practical approach. *British journal of haematology* 2006; 134:294-301.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch